<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEUPROLIDE ACETATE <img border="0" src="../images/pr.gif"/></span><br/>(loo-proe'lide)<br/><span class="topboxtradename">Eligard, </span><span class="topboxtradename">Lupron, </span><span class="topboxtradename">Lupron Depot, </span><span class="topboxtradename">Lupron Depot-Ped, </span><span class="topboxtradename">Viadur<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">gonadotropin-releasing hormone analog</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg/mL injection; 3.75 mg, 7.5 mg, 11.25 mg, 15 mg, 22.5 mg, 30 mg microspheres for injection (depot formulations); 65 mg implant</p>
<h1><a name="action">Actions</a></h1>
<p>Occupies and desensitizes pituitary GnRH receptors, resulting initially in release of gonadotropins LH and FSH and stimulation
         of ovarian and testicular steroidogenesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Long-term administration suppresses both gonadotropin secretion and steroidogenesis and leads to prostatic and testicular
         atrophy. <b>Antitumor effect:</b> May inhibit growth of hormone-dependent tumors as indicated by reduction in concentrations of PSA and serum testosterone
         to levels equal to or less than pretreatment levels. <b>Contraceptive effect:</b> By inhibiting gonadotropin release, ovulation or spermatogenesis is suppressed.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative treatment of advanced prostatic carcinoma as alternative to orchiectomy or estrogen administration; endometriosis;
         anemia caused by leiomyomata.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Breast cancer; male contraceptive; delayed puberty.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Following orchiectomy or estrogen therapy; metastatic cerebral lesions; pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Life-threatening carcinoma in which rapid symptomatic relief is necessary; known hypersensitivity to benzyl alcohol.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Palliative Treatment for Prostate Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 1 mg/d <span class="rdroute">IM</span> 7.5 mg/mo or 22.5 mg q3mo or 30 mg q4mo (depot preparation) <span class="rdroute">Implant</span> one implant q12mo<br/><br/><span class="indicationtitle">Endometriosis, Anemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 3.75 mg qmo or 11.25 mg q3mo<br/><br/><span class="indicationtitle">Precocious Puberty</span><br/><span class="rdage">Child:</span> <span class="rdroute">IM</span> Depot-Ped, 0.150.3 mg/kg q28d (min: 7.5 mg), titrate by 3.75-mg increments q4wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Do not use Depot-Ped form for SC injection.</li>
<li>Rotate injection sites.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Prepare solution for Depot-Ped injection using a 22-gauge needle (or syringe provided by manufacturer), withdraw 1.5 mL of
            diluent from the supplied ampul and inject it into the vial. Shake well to form a uniform suspension. Withdraw entire contents
            and administer immediately.
         </li>
<li>Do not administer parenteral drug formulation if particulate matter or discoloration is present.</li>
<li>Refrigerate unopened vials. Store vial in use at room temperature for several months with minimal loss of potency. Protect
            from light and freezing.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Disease flare (worsening of S&amp;S of carcinoma),</span> injection site irritation, asthenia, fatigue, fever, facial swelling. <span class="typehead">CNS:</span> Dizziness, pain, headache, paresthesia. <span class="typehead">CV:</span> <span class="speceff-common">Peripheral edema,</span> cardiac arrhythmias, <span class="speceff-life">MI</span>. <span class="typehead">Endocrine:</span> <span class="speceff-common">Hot flushes, impotence, decreased libido,</span> gynecomastia, breast tenderness, amenorrhea, vaginal bleeding, thyroid enlargement, hypoglycemia. <span class="typehead">GI:</span> Nausea, vomiting, constipation, anorexia, sour taste, GI bleeding, diarrhea. <span class="typehead">Musculoskeletal:</span> Increased bone pain, myalgia. <span class="typehead">Renal:</span> Increased hematuria, dysuria, flank pain. <span class="typehead">Respiratory:</span> Pleural rub, pulmonary fibrosis flare. <span class="typehead">Hematologic:</span> Decreased Hct, Hgb. <span class="typehead">Skin:</span> Pruritus, rash, hair loss. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">androgens</span>, <span class="classification">estrogens</span> would counteract therapeutic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from SC or IM sites. <span class="typehead">Metabolism:</span> Metabolized by enzymes in hypothalamus and anterior pituitary. <span class="typehead">Half-Life:</span> 3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor PSA and testosterone levels in males with prostate cancer. A gradual rise in values after their decrease may signify
            treatment failure.
         </li>
<li>Inspect injection site. If local hypersensitivity reactions occur (erythema, induration), suspect sensitivity to benzyl alcohol.
            Report to physician.
         </li>
<li>Monitor I&amp;O ratio and pattern. Report hematuria and decreased output. Carefully monitor voiding problems.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>When used for prostate cancer, bone pain and voiding problems (i.e., symptoms of tumor obstruction) usually increase during
            first several weeks of continuous treatment but are transient. Hot flushes also may be experienced.
         </li>
<li>Notify physician of neurologic S&amp;S (paresthesia and weakness in lower limbs). Exercise caution when walking without assistance.</li>
<li>When used for endometriosis. Continuous treatment may cause amenorrhea and other menstrual irregularities.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>